Canada Pension Plan Investment Board
SPRY icon

Canada Pension Plan Investment Board’s ARS Pharmaceuticals SPRY Stock Holding History

Canada Pension Plan Investment Board’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$237K Hold
29,600
– – ﹤0.01% 1550
2026
Q1 		$238K Hold
29,600
– – ﹤0.01% 1508
2025
Q4 		$345K Buy
+29,600
New +$288K ﹤0.01% 1457

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Canada Pension Plan Investment Board's SPRY Position: Q2 2026 in Review

Canada Pension Plan Investment Board held its ARS Pharmaceuticals (SPRY) position steady in Q2 2026 at 29,600 shares worth $237K. The position accounts for ﹤0.01% of the portfolio, ranked #1550.

Canada Pension Plan Investment Board first reported a position in SPRY in Q4 2025 and has held it in 3 quarters since. The position peaked at $345K in Q4 2025. 208 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • Canada Pension Plan Investment Board held 29,600 shares of ARS Pharmaceuticals worth $237K as of Q2 2026.
  • Canada Pension Plan Investment Board left its ARS Pharmaceuticals share count unchanged in Q2 2026.
  • ARS Pharmaceuticals made up ﹤0.01% of Canada Pension Plan Investment Board's portfolio in Q2 2026, its #1550 holding.
  • Canada Pension Plan Investment Board first reported a position in ARS Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Canada Pension Plan Investment Board's ARS Pharmaceuticals position peaked at $345K in Q4 2025.
  • 208 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Canada Pension Plan Investment Board's 13F filing for Q2 2026, filed 14 Aug 2026.